Intraductal papillary neoplasms of the bile duct: a European retrospective multicenter observational study (EUR-IPNB study).


Journal

International journal of surgery (London, England)
ISSN: 1743-9159
Titre abrégé: Int J Surg
Pays: United States
ID NLM: 101228232

Informations de publication

Date de publication:
01 Apr 2023
Historique:
received: 31 08 2022
accepted: 19 01 2023
medline: 27 4 2023
pubmed: 15 3 2023
entrez: 14 3 2023
Statut: epublish

Résumé

Intraductal papillary neoplasm of the bile duct (IPNB) is a rare disease in Western countries. The main aim of this study was to characterize current surgical strategies and outcomes in the mainly European participating centers. A multi-institutional retrospective series of patients with a diagnosis of IPNB undergoing surgery between 1 January 2010 and 31 December 2020 was gathered under the auspices of the European-African Hepato-Pancreato-Biliary Association. The textbook outcome (TO) was defined as a non-prolonged length of hospital stay plus the absence of any Clavien-Dindo grade at least III complications, readmission, or mortality within 90 postoperative days. A total of 28 centers contributed 85 patients who underwent surgery for IPNB. The median age was 66 years (55-72), 49.4% were women, and 87.1% were Caucasian. Open surgery was performed in 72 patients (84.7%) and laparoscopic in 13 (15.3%). TO was achieved in 54.1% of patients, reaching 63.8% after liver resection and 32.0% after pancreas resection. Median overall survival was 5.72 years, with 5-year overall survival of 63% (95% CI: 50-82). Overall survival was better in patients with Charlson comorbidity score 4 or less versus more than 4 ( P =0.016), intrahepatic versus extrahepatic tumor ( P =0.027), single versus multiple tumors ( P =0.007), those who underwent hepatic versus pancreatic resection ( P =0.017), or achieved versus failed TO ( P =0.029). Multivariable Cox regression analysis showed that not achieving TO (HR: 4.20; 95% CI: 1.11-15.94; P =0.03) was an independent prognostic factor of poor overall survival. Patients undergoing liver resection for IPNB were more likely to achieve a TO outcome than those requiring a pancreatic resection. Comorbidity, tumor location, and tumor multiplicity influenced overall survival. TO was an independent prognostic factor of overall survival.

Sections du résumé

BACKGROUND/PURPOSE OBJECTIVE
Intraductal papillary neoplasm of the bile duct (IPNB) is a rare disease in Western countries. The main aim of this study was to characterize current surgical strategies and outcomes in the mainly European participating centers.
METHODS METHODS
A multi-institutional retrospective series of patients with a diagnosis of IPNB undergoing surgery between 1 January 2010 and 31 December 2020 was gathered under the auspices of the European-African Hepato-Pancreato-Biliary Association. The textbook outcome (TO) was defined as a non-prolonged length of hospital stay plus the absence of any Clavien-Dindo grade at least III complications, readmission, or mortality within 90 postoperative days.
RESULTS RESULTS
A total of 28 centers contributed 85 patients who underwent surgery for IPNB. The median age was 66 years (55-72), 49.4% were women, and 87.1% were Caucasian. Open surgery was performed in 72 patients (84.7%) and laparoscopic in 13 (15.3%). TO was achieved in 54.1% of patients, reaching 63.8% after liver resection and 32.0% after pancreas resection. Median overall survival was 5.72 years, with 5-year overall survival of 63% (95% CI: 50-82). Overall survival was better in patients with Charlson comorbidity score 4 or less versus more than 4 ( P =0.016), intrahepatic versus extrahepatic tumor ( P =0.027), single versus multiple tumors ( P =0.007), those who underwent hepatic versus pancreatic resection ( P =0.017), or achieved versus failed TO ( P =0.029). Multivariable Cox regression analysis showed that not achieving TO (HR: 4.20; 95% CI: 1.11-15.94; P =0.03) was an independent prognostic factor of poor overall survival.
CONCLUSIONS CONCLUSIONS
Patients undergoing liver resection for IPNB were more likely to achieve a TO outcome than those requiring a pancreatic resection. Comorbidity, tumor location, and tumor multiplicity influenced overall survival. TO was an independent prognostic factor of overall survival.

Identifiants

pubmed: 36917142
doi: 10.1097/JS9.0000000000000280
pii: 01279778-202304000-00013
pmc: PMC10389541
doi:

Types de publication

Observational Study Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

760-771

Informations de copyright

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

Références

Ainechi S, Lee H. Updates on precancerous lesions of the biliary tract: biliary precancerous lesion. Arch Pathol Lab Med 2016;140:1285–1289.
Desjonqueres E, Campani C, Marra F, et al. Preneoplastic lesions in the liver: molecular insights and relevance for clinical practice. Liver Int 2022;42:492–506.
Lendvai G, Szekerczés T, Illyés I, et al. Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis. Pathol Oncol Res 2020;26:3–15.
Aslam A, Wasnik AP, Shi J, et al. Intraductal papillary neoplasm of the bile duct (IPNB): CT and MRI appearance with radiology–pathology correlation. Clin Imaging 2020;66(April):10–17.
IARC Publications. Digestive System Tumors WHO Classification of Tumours Series, 5th ed, Vol 1. International Agency for Research on Cancer; 2019.
Klöppel G, Adsay V, Konukiewitz B, et al. Precancerous lesions of the biliary tree. Best Pract Res Clin Gastroenterol 2013;27:285–297.
Rocha FG, Lee H, Katabi N, et al. Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology 2012;56:1352–1360.
Onoe S, Ebata T, Yokoyama Y, et al. A clinicopathological reappraisal of intraductal papillary neoplasm of the bile duct (IPNB): a continuous spectrum with papillary cholangiocarcinoma in 181 curatively resected cases. HPB 2021;23:1525–1532.
Kubota K, Jang JY, Nakanuma Y, et al. Clinicopathological characteristics of intraductal papillary neoplasm of the bile duct: a Japan–Korea collaborative study. J Hepatobiliary Pancreat Sci 2020;27:581–597.
Tan Y, Milikowski C, Toribio Y, et al. Intraductal papillary neoplasm of the bile ducts: a case report and literature review. World J Gastroenterol 2015;21:12498–12504.
Schlitter AM, Born D, Bettstetter M, et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 2014;27:73–86.
Van Roessel S, Mackay TM, Van Dieren S, et al. Textbook outcome: nationwide analysis of a novel quality measure in pancreatic surgery. Ann Surg 2020;271:155–162.
Mehta R, Tsilimigras DI, Paredes AZ, et al. Dedicated cancer centers are more likely to achieve a textbook outcome following hepatopancreatic surgery. Ann Surg Oncol 2020;27:1889–1897.
Merath K, Chen Q, Bagante F, et al. Textbook outcomes among medicare patients undergoing hepatopancreatic surgery. Ann Surg 2020;271:1116–1123.
Mathew G, Agha R. STROCSS Group. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case–control studies in surgery. Int J Surg 2021;96(November):106165.
Roffman CE, Buchanan J, Allison GT. Charlson comorbidities index. J Physiother 2016;62:171.
Halls MC, Berardi G, Cipriani F, et al. Development and validation of a difficulty score to predict intraoperative complications during laparoscopic liver resection. Br J Surg 2018;105:1182–1191.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205–213.
Brooke-Smith M, Figueras J, Ullah S, et al. Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study. HPB 2015;17:46–51.
Rahbari NN, Garden OJ, Padbury R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011;149:713–724.
Rahbari NN, Garden OJ, Padbury R, et al. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB 2011;13:528–535.
Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 2017;161:584–591.
Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery 2007;142:761–768.
Schlitter AM, Jang KT, Klöppel G, et al. Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol 2015;28:1249–1264.
Zen Y, Pedica F, Patcha VR, et al. Mucinous cystic neoplasms of the liver: a clinicopathological study and comparison with intraductal papillary neoplasms of the bile duct. Mod Pathol 2011;24:1079–1089.
Campbell F, Cairns A, Duthie F, et al. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of vater and common bile duct. The Royal College of Pathologists; 2017. www.rcpath.org
Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.
Gyawali B, Eisenhauer E, Tregear M, et al. Progression-free survival: it is time for a new name. Lancet Oncol 2022;23:328–330.
Gordon-Weeks AN, Jones K, Harriss E, et al. Systematic review and meta-analysis of current experience in treating IPNB clinical and pathologica l corre lates. Ann Surg 2016;263:656–663.
Zen Y, Jang KT, Ahn S, et al. Intraductal papillary neoplasms and mucinous cystic neoplasms of the hepatobiliary system: demographic differences between Asian and Western populations, and comparison with pancreatic counterparts. Histopathology 2014;65:164–173.
D’Souza MA, Isaksson B, Löhr M, et al. The clinicopathological spectrum and management of intraductal papillary mucinous neoplasm of the bile duct (IPMN-B). Scand J Gastroenterol 2013;48:473–479.
Woodhouse B, Panesar D, Koea J. Quality performance indicators for hepato-pancreatico-biliary procedures: a systematic review. HPB (Oxford) 2021;23:1–10.
Vibert E, Dokmak S, Belghiti J. Surgical strategy of biliary papillomatosis in Western countries. J Hepatobiliary Pancreat Sci 2010;17:241–245.
Matsumoto T, Kubota K, Hachiya H, et al. Impact of tumor location on postoperative outcome of intraductal papillary neoplasm of the bile duct. World J Surg 2019;43:1313–1322.
Kang MJ, Jang JY, Lee KB, et al. Impact of macroscopic morphology, multifocality, and mucin secretion on survival outcome of intraductal papillary neoplasm of the bile duct. J Gastrointest Surg 2013;17:931–938.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Hepatobiliary Cancers, version 2; 2022. Accessed 24 August 2022. https://www.nccn.org/guidelines/recently-published-guidelines
Kim WJ, Hwang S, Lee YJ, et al. Clinicopathological features and long-term outcomes of intraductal papillary neoplasms of the intrahepatic bile duct. J Gastrointest Surg 2016;20:1368–1375.
Luvira V, Pugkhem A, Bhudhisawasdi V, et al. Long-term outcome of surgical resection for intraductal papillary neoplasm of the bile duct. J Gastroenterol Hepatol 2017;32:527–533.
Kim JR, Lee KB, Kwon W, et al. Comparison of the clinicopathologic characteristics of intraductal papillary neoplasm of the bile duct according to morphological and anatomical classifications. J Korean Med Sci 2018;33:e266.
Uemura S, Higuchi R, Yazawa T, et al. Prognostic factors for surgically resected intraductal papillary neoplasm of the bile duct: a retrospective cohort study. Ann Surg Oncol 2021;28:826–834.
Kim JR, Jang KT, Jang JY, et al. Clinicopathologic analysis of intraductal papillary neoplasm of bile duct: Korean multicenter cohort study. HPB (Oxford) 2020;22:1139–1148.

Auteurs

Núria Lluís (N)

Division of Hepatobiliary and Pancreas Surgery, Miami Cancer Institute, Miami, Florida, USA.

Mario Serradilla-Martín (M)

Department of Surgery, Instituto de Investigación Sanitaria Aragón, Miguel Servet University Hospital, Zaragoza.

Mar Achalandabaso (M)

HPB Surgery and Transplantation, Hospital Universitario Vall d'Hebron.

François Jehaes (F)

Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, Assistance Publique Hôpitaux de Paris, University of Paris Cité, Clichy, France.

Bobby V M Dasari (BVM)

Liver Transplant and HPB Surgery, Queen Elizabeth Hospital, Birmingham, UK.

Sara Mambrilla-Herrero (S)

Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao.

Ernesto Sparrelid (E)

Department of Clinical Science, Division of Surgery, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.

Anita Balakrishnan (A)

Cambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust.
Department of Surgery, University of Cambridge, Cambridge.

Frederik J H Hoogwater (FJH)

Department of HPB Surgery and Liver Transplantation, and Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Maria J Amaral (MJ)

Department of General Surgery, Centro Hospitalar e Universitário de Coimbra.
Faculty of Medicine, University of Coimbra, Coimbra.

Bodil Andersson (B)

Department of Surgery, Lund University.
Skane University Hospital, Lund.

Frederik Berrevoet (F)

Department of General and HPB Surgery, and Liver Transplantation, University Hospital Gent, Gent.

Alexandre Doussot (A)

Department of Digestive Surgical Oncology, Liver Transplantation Unit, CHU Besançon, Besancon.

Víctor López-López (V)

Department of General, Visceral and Transplantation Surgery, Clinic and University Hospital Virgen de La Arrixaca, IMIB-ARRIXACA, Murcia.

Mohammedsuror Alsammani (M)

WITS University, Johannesburg, South Africa.

Olivier Detry (O)

Department of Abdominal Surgery and Transplantation, CHU Liege, University of Liege.

Carlos Domingo-Del Pozo (C)

Department of General and Digestive Surgery, Hospital Doctor Peset, Valencia, Spain.

Nikolaos Machairas (N)

Second Department of Propaedeutic Surgery, National and Kapodistrian University of Athens.

Damján Pekli (D)

Department of Surgery, Transplantation and Gastroenterology, Semmelweis University, Budapest, Hungary.

Cándido F Alcázar-López (CF)

HPB Surgery and Liver Transplantation, Dr. Balmis General University Hospital, and Alicante Institute for Health and Biomedical Research (ISABIAL).

Horacio Asbun (H)

Division of Hepatobiliary and Pancreas Surgery, Miami Cancer Institute, Miami, Florida, USA.

Bergthor Björnsson (B)

Department of Surgery in Linköping and Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Thalis Christophides (T)

General Surgery Department, HPB Division, Nicosia General Hospital, Nicosia, Cyprus.

Alberto Díez-Caballero (A)

Quirúrgica Cirujanos Asociados, Centro Médico Teknon, Barcelona.

David Francart (D)

Department of Abdominal Surgery, CHC Groupe Santé, Liège, Belgium.

Colin B Noel (CB)

HPB Clinical Unit, Gastrointestinal Surgery, Universitas Academic Hospital, University of the Free State, Bloemfontein.

Donzília Sousa-Silva (D)

Department of Surgery, HEBIPA - Hepatobiliary and Pancreatic Unit, Hospital de Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Enrique Toledo-Martínez (E)

Servicio de Cirugía, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.

George N Tzimas (GN)

Hepatobiliary Surgery Department, Hygeia Hospital, Athens, Greece.

Sheraz Yaqub (S)

Department of HPB Surgery, Oslo University Hospital.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

François Cauchy (F)

Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, Assistance Publique Hôpitaux de Paris, University of Paris Cité, Clichy, France.

Mikel Prieto-Calvo (M)

Hepatobiliary Surgery and Liver Transplant Unit, Cruces University Hospital, Bilbao.

Melroy A D'Souza (MA)

Department of Clinical Science, Division of Surgery, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm.

Harry V M Spiers (HVM)

Cambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust.
Department of Surgery, University of Cambridge, Cambridge.

Marius C van den Heuvel (MC)

Department of HPB Surgery and Liver Transplantation, and Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Ramón Charco (R)

HPB Surgery and Transplantation, Hospital Universitario Vall d'Hebron.

Mickaël Lesurtel (M)

Department of HPB Surgery and Liver Transplantation, Beaujon Hospital, Assistance Publique Hôpitaux de Paris, University of Paris Cité, Clichy, France.

José M Ramia (JM)

HPB Surgery and Liver Transplantation, Dr. Balmis General University Hospital, and Alicante Institute for Health and Biomedical Research (ISABIAL).
Miguel Hernández University, Alicante.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH